Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
acute lymphoblastic leukemia
Biotech
Autolus outlines path to FDA after CAR-T trial hits endpoint
Autolus Therapeutics' phase 2 trial hit the primary endpoint at an interim analysis, and it is setting plans for more data to file for FDA approval.
Nick Paul Taylor
Dec 9, 2022 9:15am
New study bolsters support for novel 'off-the-shelf' CAR-T cells
Apr 25, 2022 11:30am
Blackstone bets on Autolus' CD19 CAR-T in $250M deal
Nov 8, 2021 7:15am
Erytech's eryaspase flunks late-stage pancreatic cancer trial
Oct 25, 2021 10:52am
Takeda blood cancer drug flunks phase 3 in setback to R&D plans
Sep 2, 2021 8:55am
Early Syndax data broach 'undruggable' leukemia mutation
Apr 27, 2020 4:05pm